Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anavex Life SciencesAVXL +7.08%30 EV-to-EBITDA is -4.29 as of Aug. 03, 2026. GuruFocus rates AVXL with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 416 Biotechnology companies, Anavex Life Sciences ranks worse than 240384.38% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Anavex Life Sciences's enterprise value is $145.97 Mil.
Anavex Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-34.03 Mil. Therefore, Anavex Life Sciences's EV-to-EBITDA for today is -4.29.
The historical rank and industry rank for Anavex Life Sciences's EV-to-EBITDA or its related term are showing as below:
AVXL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.32 Med: 0 Max: 0
Current: -4.29
AVXL's EV-to-EBITDA is ranked worse than 100% of 416
companies
in the Biotechnology industry
Industry Median: 11.9
vs AVXL: -4.29
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Anavex Life Sciences (NAS:AVXL) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Anavex Life Sciences's PE Ratio (TTM) for today is calculated as:
Anavex Life Sciences's share price for today is $2.95.
Anavex Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.390.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Anavex Life Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Anavex Life Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anavex Life Sciences EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Anavex Life Sciences's EV-to-EBITDA falls into.
Anavex Life Sciences's current Enterprise Value is $145.97 Mil.
Anavex Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-34.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anavex Life Sciences (AVXL) has a EV-to-EBITDA of -4.29 as of Aug. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Anavex Life Sciences. According to the industry distribution chart, Anavex Life Sciences ranks #999999 out of 416 companies in the Biotechnology industry.
Is Anavex Life Sciences' EV-to-EBITDA too high?
Anavex Life Sciences' current EV-to-EBITDA is -4.29. Based on the distribution chart, Anavex Life Sciences ranks #999999 out of 416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Anavex Life Sciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Anavex Life Sciences' EV-to-EBITDA compare to OBIO and TARA?
According to the Biotechnology industry distribution chart, Anavex Life Sciences ranks #999999 out of 416 companies for EV-to-EBITDA. This places Anavex Life Sciences in the lower half of its industry. The industry median EV-to-EBITDA is 11.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.90, based on 416 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Anavex Life Sciences. For the Biotechnology industry, the median EV-to-EBITDA is 11.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anavex Life Sciences's current EV-to-EBITDA is -4.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anavex Life Sciences stock overvalued right now?
Anavex Life Sciences (AVXL) has a current EV-to-EBITDA of -4.29. The current EV-to-EBITDA is -4.29. Anavex Life Sciences' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Anavex Life Sciences (AVXL), the current EV-to-EBITDA is -4.29 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
30GF Score
Get the complete analysis for AVXL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVXL has been successfully added to your 
